Continuous glucose monitors (CGMs) and health wearables are no longer curiosities for the tech-savvy elite. In 2026, patients are walking into Indian OPDs with two weeks of glucose trend data on their phones, heart rate variability charts, and sleep quality reports — and asking you what it all means. This is both an opportunity and a challenge. Here is how to use this technology to improve care, without drowning in noise. The CGM Landscape in India The most widely used CGMs in India are: Abbott FreeStyle Libre (2 and 3): Flash glucose monitoring with optional alarms; Libre 3 provides real-time glucose values on the phone. Available in India, cost approximately ₹2,500–3,500 per sensor (14-day wear). Dexcom G7: Real-time CGM with alarms, smartphone connectivity; higher cost, approximately ₹4,000–5,000 per sensor. Medtronic Guardian Connect: Used primarily with insulin pumps in specialist settings. Insurance coverage for CGM in India is limited — most patients pay out of pocket, making cost a recurring discussion in your OPD. Which Patients Benefit Most from CGM? Strongest evidence: Type 1 diabetes — universal recommendation; CGM reduces HbA1c and hypoglycaemia frequency Type 2 diabetes on insulin (basal-bolus or intensive regimens) — reduces hypoglycaemia, improves time in range Patients with hypoglycaemia unawareness Increasingly recommended: Type 2 on sulphonylureas — hypoglycaemia risk is real and often underestimated Gestational diabetes — detecting post-prandial spikes that fasting glucose misses Any patient with unstable glycaemic control Lower yield (but sometimes useful for motivation): Well-controlled Type 2 on oral medications — may help identify post-meal spikes and reinforce dietary choices Reading the CGM Report: Time in Range (TIR) HbA1c is a retrospective average. TIR tells you what is happening in real time. Consensus targets: Time in Range (3.9–10 mmol/L or 70–180 mg/dL): >70% for most adults with T2DM; >50% for frail elderly patients Time Below Range (<3.9 mmol/L): <4% Time Above Range (>10 mmol/L): <25% Making Sense of CGMs & Wearables in Your OPD (India, 2026) Continuous glucose monitors (CGMs) and health wearables are now routine in Indian OPDs. Patients walk in with two weeks of glucose trends, HRV charts, and sleep reports — and expect you to interpret them. Used well, this data can sharpen your clinical decisions without overwhelming you. 1. CGM Landscape in India Commonly seen devices: Abbott FreeStyle Libre 2 / 3 Flash (Libre 2) and real-time (Libre 3) glucose monitoring Optional alarms; phone connectivity ~₹2,500–3,500 per 14‑day sensor Widely available in India Dexcom G7 Real-time CGM with alarms and app integration ~₹4,000–5,000 per sensor Medtronic Guardian Connect Primarily used with insulin pumps in specialist/endocrine setups Cost & access: Insurance coverage is limited; most patients pay out of pocket. Expect cost–benefit discussions at almost every visit. 2. Who Benefits Most from CGM? Strongest evidence Type 1 diabetes Should be on CGM wherever feasible Lowers HbA1c and reduces hypoglycaemia Type 2 diabetes on insulin (basal–bolus/intensive) Better time in range (TIR) Fewer hypoglycaemic episodes Hypoglycaemia unawareness Alerts and trends improve safety Increasingly recommended Type 2 on sulphonylureas Real hypoglycaemia risk, often missed by spot sugars Gestational diabetes Captures post‑prandial spikes that fasting sugars and even HbA1c miss Any patient with unstable control despite medication changes Lower yield (but motivational) Well‑controlled Type 2 on orals Can reveal post‑meal spikes Useful for diet counselling and adherence 3. Reading CGM Reports: Focus on Time in Range (TIR) HbA1c is a long‑term average; CGM shows day‑to‑day reality. Standard targets (for most adults with T2DM): Time in Range (TIR) 70–180 mg/dL (3.9–10 mmol/L): >70% Time Below Range (TBR) <70 mg/dL (<3.9 mmol/L): <4% Time Above Range (TAR) >180 mg/dL (>10 mmol/L): <25% For frail elderly, a TIR >50% with minimal hypoglycaemia is acceptable. Clinical pearl: A patient with HbA1c 7.5% but high TBR is not well controlled — frequent lows are masking overall control. CGM exposes this and guides safer titration. When reviewing a 14‑day report in OPD: Look at overall TIR/TBR/TAR first. Then scan daily patterns (same time of day, same meals). Adjust therapy based on recurring patterns, not isolated spikes. 4. What Wearables Are Bringing to Your Desk Common devices: Apple Watch, Samsung Galaxy Watch, Fitbit, Garmin. They typically provide: Heart rate & HRV (heart rate variability)